期刊
RHEUMATOLOGY
卷 59, 期 3, 页码 469-477出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kez572
关键词
idiopathic inflammatory myopathy; myositis; dermatomyositis; cancer-associated dermatomyositis; myositis specific antibody; TIF1-gamma; cancer
类别
Anti-transcription intermediary factor 1 (TIF1)-gamma autoantibodies are robustly linked with cancer-associated DM in adults. This review aims to give an overview of the physiological context of TIF1-gamma and to determine whether there is a pathophysiological link between anti-TIF1-gamma autoantibodies and the occurrence of cancer. Detection of anti-TIF1-gamma autoantibodies has a high sensitivity and specificity for cancer-associated DM in adults and is therefore useful for both diagnosis and cancer risk stratification. The function of the autoantigen, TIF1-gamma, may provide insight into the mechanism behind this association. TIF1-gamma is a ubiquitously present protein involved in various biological pathways, including TGF-beta signalling. In cancer, it can act either as a tumour suppressor or promoter, depending on the cellular context and cancer stage. Evolving data provide pathophysiological insights, linking anti-TIF1-gamma autoantibodies to both the anti-tumour response and to muscle and skin damage. TIF1-gamma expression is increased in muscle and skin tissue of patients with DM. Mutations or loss-of-heterozygosity in TIF1-gamma alleles in malignant tissue may result in the expression of tumour-specific neo-antigens stimulating autoantibody production. The newly formed autoantibodies are hypothesized to cross-react with antigens in muscle and skin, driving the development of DM. Based on the current evidence, anti-TIF1-gamma autoantibodies should be considered warning lights of a potential tumour autoantigen and should alert the physician to the possibility of an underlying cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据